ClinicalTrials.gg
CompletedNCT03599063Updated Nov 8, 2019

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

A Phase 1 interventional study of PF-06946860 and Placebo in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-08.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2019, 7 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06946860 in healthy adult subjects following single ascending doses This is the first clinical study of PF-06946860.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy female subjects of nonchildbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive
  • (BMI) within 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb)
  • Evidence of a personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study
  • Subjects enrolling as Japanese must have four biologically Japanese grandparents born in Japan.

Key Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing.
  • History of allergic reactions to diagnostic or therapeutic protein or human albumin.
  • History of recurrent infections or active infection within 28 days of screening.
  • Exposure to within 28 days of screening.
  • History of regular alcohol consumption or positive drug test
  • Treatment with an drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of IP (whichever is longer).
  • Fertile male subjects who are unwilling or unable to use a highly effective method of for the duration of the study and for at least 28 days after the last dose.
  • Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Single subcutaneous administration of PF-06946860 at planned dose level 0.1 mg, or placebo

    Biological: PF-06946860 · Other: Placebo

  • Experimental
    Cohort 2

    Single subcutaneous administration of PF-06946860 at planned dose level 0.3 mg, or placebo

    Biological: PF-06946860 · Other: Placebo

  • Experimental
    Cohort 3

    Single subcutaneous administration of PF-06946860 at planned dose level 1 mg, or placebo

    Biological: PF-06946860 · Other: Placebo

  • Experimental
    Cohort 4

    Single subcutaneous administration of PF-06946860 at planned dose level 3 mg, or placebo

    Biological: PF-06946860 · Other: Placebo

  • Experimental
    Cohort 5

    Single subcutaneous administration of PF-06946860 at planned dose level 10 mg, or placebo

    Biological: PF-06946860 · Other: Placebo

  • Experimental
    Cohort 6

    Single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo

    Biological: PF-06946860 · Other: Placebo

  • Experimental
    Cohort 7

    Single subcutaneous administration of PF-06946860 at planned dose level 100 mg, or placebo

    Biological: PF-06946860 · Other: Placebo

  • Experimental
    Optional: Cohort 8

    Optional: single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo in healthy Japanese subjects

    Biological: PF-06946860 · Other: Placebo

Interventions

  • BiologicalPF-06946860

    PF-06946860 administered subcutaneously

  • OtherPlacebo

    Placebo, administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Incidence of participants experiencing AE.

    Time frame: Up 9 weeks post dose

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Baseline, up to 9 weeks post dose, as data permit

  2. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Time frame: Baseline, up to 9 weeks post dose, as data permit

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Baseline, up to 9 weeks post dose, as data permit

  4. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Baseline, up to 9 weeks post dose, as data permit

  5. Incidence of development of ADA, and if necessary NAb, against PF-06946860

    Time frame: Baseline, up to 9 weeks post-dose, as data permit

07

Study locations

1 site
  • Pfizer New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Sep 2019, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2018
First posted
Jul 26, 2018
StartActual
Jul 30, 2018
Primary completionActual
Sep 18, 2019
CompletionActual
Sep 18, 2019
Last update
Nov 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03599063
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
Jul 30, 2018
Primary completion
Sep 18, 2019
Completion
Sep 18, 2019
Last update
Nov 8, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponsegromab

Start the discussion